The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 31, 1995

Filed:

Jan. 06, 1994
Applicant:
Inventors:

Tesfaye Biftu, Belmont, MA (US);

Xiong Cai, Framingham, MA (US);

Sajjet Hussion, Lexington, MA (US);

Gurmit Grewal, Waltham, MA (US);

T Y Shen, Charlottesville, VA (US);

Assignee:

Cytomed, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D / ; C07D / ; C07C / ;
U.S. Cl.
CPC ...
549 71 ; 549 72 ; 549 73 ; 549 75 ; 549 76 ; 549 77 ; 549 78 ; 549 79 ; 549484 ; 549488 ; 549491 ; 549496 ; 549498 ; 549499 ; 549500 ; 549501 ; 549502 ; 562426 ; 562429 ; 562430 ; 562432 ; 562439 ; 562442 ; 562451 ; 562452 ; 562455 ; 564 47 ; 564 48 ; 564 49 ; 564 50 ; 564 52 ; 564123 ; 564152 ; 564153 ; 564154 ; 564155 ; 564150 ; 564157 ; 564158 ; 568 27 ; 568 28 ; 568 33 ; 568 37 ; 568631 ; 568647 ; 568648 ; 568649 ;
Abstract

2,5-Diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i,e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase. Also disclosed is a method to treat disorders mediated by PAF and/or leukotrienes that includes administering an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, to a patient in need of such therapy.


Find Patent Forward Citations

Loading…